Open Orphan (ORPH) Investor Presentation June 2021 June 3, 2021 – Posted in: Blog, Open Orphan (ORPH)
Open Orphan (ORPH) Investor Presentation June 2021.
Continue reading
Open Orphan (ORPH) Investor Presentation June 2021.
Continue reading(Interview starts at 12 minutes 20 seconds)
Continue readingOpen Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform, enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform. The platform is expected to be completed and rolled out in Q1 2020. The five companies signed up to the Genomic Health DataBANK platform will ensure the database is ‘fit-for-purpose’ from a pharmaceutical and data analysis perspective ahead of the first patient data upload. This builds…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience (“Carna”) (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences (“Venn”), part…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending the Jefferies 2019 London Healthcare Conference on 20th-21st November 2019 in London, UK. The conference will be attended by a range of international healthcare executives and institutional investors who will gather to address near and long-term investment opportunities and to discuss the mechanisms driving global healthcare. Open Orphan’s Chief Executive Officer, Cathal Friel, will be in attendance and will…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30th October 2019 at 19:00 (UK time). Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the Company’s Genomic Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Maurice will also discuss how and why…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at The London Investor Show at Novotel London West, London, W6 8DR this Friday 25th October 2019. Maurice Treacy, Open Orphan’s Chief Commercial Officer, will be in attendance and will be presenting in Conference Room 1 from 11:50am – 12:20pm. Afterwards there will be an opportunity for existing and potential shareholders to discuss the Company’s business plans…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at Shares Investor Evening at Macdonald Manchester Hotel, Manchester, M1 2PG from 18:00 on Thursday 10th October. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance and will be presenting to update existing and potential investors on the Company’s business plans for 2019. The event will provide an opportunity for investors to hear about the progress being…
Continue reading